PRCT — Procept Biorobotics Share Price
0.000.00%
Last trade - 00:00- $3.50bn
- $3.33bn
- $136.19m
- 32
- 11
- 85
- 38
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 13.26 | ||
| Price to Tang. Book | 13.32 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 22.4 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -31.5% | ||
| Return on Equity | -47.29% | ||
| Operating Margin | -69.37% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 6.17 | 7.72 | 34.47 | 75.01 | 136.19 | 213.73 | 300.42 | 116.76% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
PROCEPT BioRobotics Corporation is a surgical robotics company, which is focused on advancing patient care by developing transformative solutions in urology. The Company develops, manufactures and sells the AquaBeam Robotic System, which is an image-guided surgical robotic system for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia (BPH). The AquaBeam Robotic System employs a single-use disposable handpiece to deliver the Company’s proprietary Aquablation therapy, which combines real-time, multi-dimensional imaging, personalized treatment planning, automated robotics and heat-free waterjet ablation for targeted and rapid removal of prostate tissue. The Company designed Aquablation therapy to deliver effective, safe and durable outcomes for males suffering from lower urinary tract symptoms, (LUTS), due to BPH that are independent of prostate size and shape or surgeon experience.
Directors
- Frederic Moll CHM
- Reza Zadno PRE
- Kevin Waters CFO
- Surag Mantri SVP
- Matthew Salkeld VPR
- Taylor Harris DRC (45)
- Last Annual
- December 31st, 2023
- Last Interim
- March 31st, 2024
- Incorporated
- January 29th, 2021
- Public Since
- September 15th, 2021
- No. of Shareholders
- 196
- No. of Employees
- 626
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
- NASDAQ Global Market
- Shares in Issue
- 51,424,151
- Address
- 150 Baytech Drive, SAN JOSE, 95134
- Web
- https://www.procept-biorobotics.com/
- Phone
- +1 6502329832
- Auditors
- PricewaterhouseCoopers LLP
Upcoming Events for PRCT
Procept Biorobotics Corp Annual Shareholders Meeting
Procept Biorobotics Corp at William Blair Growth Stock Conference
Procept Biorobotics Corp Annual Shareholders Meeting
Q2 2024 PROCEPT BioRobotics Corp Earnings Release
Q3 2024 PROCEPT BioRobotics Corp Earnings Release
Similar to PRCT
908 Devices.
NASDAQ Global Market
Alpha Teknova
NASDAQ Global Market
AtriCure
NASDAQ Global Market
Brainsway
NASDAQ Global Market
Castle Biosciences
NASDAQ Global Market
FAQ
What is the Procept Biorobotics share price?
As of Today at 19:17 UTC, shares in Procept Biorobotics are trading at $68.10. This share price information is delayed by 15 minutes.
How has the Procept Biorobotics share price performed this year?
Shares in Procept Biorobotics last closed at $68.10 and the price had moved by +107.43% over the past 365 days. In terms of relative price strength the Procept Biorobotics share price has outperformed the S&P500 Index by +63.97% over the past year.
What are the analyst and broker recommendations for Procept Biorobotics?
The overall consensus recommendation for Procept Biorobotics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Procept Biorobotics dividend yield?
Procept Biorobotics does not currently pay a dividend.
Does Procept Biorobotics pay a dividend?
Procept Biorobotics does not currently pay a dividend.
When does Procept Biorobotics next pay dividends?
Procept Biorobotics does not currently pay a dividend.
How do I buy Procept Biorobotics shares?
To buy shares in Procept Biorobotics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Procept Biorobotics?
As of the previous close price of $68.10, shares in Procept Biorobotics had a market capitalisation of $3.50bn.
Where are Procept Biorobotics shares listed?
Here are the trading details for Procept Biorobotics:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: PRCT
What kind of share is Procept Biorobotics?
Based on an overall assessment of its quality, value and momentum Procept Biorobotics is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Procept Biorobotics share price forecast for 2024?
The analyst consensus target price for shares in Procept Biorobotics is $71.43. That is 4.89% above the last closing price of $68.10.
Analysts covering Procept Biorobotics currently have a consensus Earnings Per Share (EPS) forecast of -$1.94 for the next financial year.
What is the trend in the Procept Biorobotics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Procept Biorobotics. Over the past six months, its share price has outperformed the S&P500 Index by +76.63%.
As of the last closing price of $68.10, shares in Procept Biorobotics were trading +63.4% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Procept Biorobotics PE Ratio?
The Procept Biorobotics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $68.10.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Procept Biorobotics?
Procept Biorobotics' management team is headed by:
- Frederic Moll - CHM
- Reza Zadno - PRE
- Kevin Waters - CFO
- Surag Mantri - SVP
- Matthew Salkeld - VPR
- Taylor Harris - DRC